Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro
LEVERKUSEN, Germany (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).
The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.
Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.
(Reporting by Frank Siebelt; Writing by Ludwig Burger)
- Tweet this
- Share this
- Digg this
- TIMELINE-The search for missing Malaysian jet
- UPDATE 3-Republican Party wins Florida congressional seat in special election
- Wild theories fill void left by missing Malaysian plane
- Malaysia military source says missing jet veered to west
- Malaysia air force denies tracking missing jet to Strait of Malacca
Made by local firm Lomus Pharmaceuticals and backed by the government, the U.S. aid agency and other donors, "Navi Malam" gel was introduced in 2011 in hospitals across Nepal and has helped to reduce the number of babies dying from umbilical cord infection. Trials have shown a 23 percent drop in newborn deaths due to infection since the gel was introduced, according to USAID. Full Article